Personalized nanovaccines can elicit robust T-cell response but identifying tumour-specific antigens sometimes remains challenging. Here these groups identify IFN-γ as a potent stimulator for the antigen presentation across a broad range of cancer cell types and then fabricating corresponding nanovaccine inducing poly-neoepitopic T-cell responses at low dosage.
- Yuwei Li
- Maoxin Fang
- Min Luo
